CompletedPhase 3

Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension

China957 participantsStarted 2021-06-10

Plain-language summary

The primary aim of the study is to assess the antihypertensive efficacy of SPH3127 in patients with mild to moderate essential hypertension.

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Male or female of age ≥18 years;
✓. Diagnosed with mild-moderate essential hypertension;
✓. Participant has understood the study-required procedures, voluntarily signed informed consent.

✕. Diagnosed with secondary hypertension, suspected grade 3 hypertension, acute hypertension, or at risk when current antihypertensive therapy discontinued;
✕. Suffered by severe heart disease within 6 months;
✕. Suffered by severe cerebrovascular disease within 6 months;
✕. Suffered by severe or malignant retinopathy;
✕. Out of controlled diabetes;
✕. History of malignant tumor;
✕. History of mental disorder;
✕. Subject is planning or in use of other antihypertensive drugs or other drugs may affect blood pressure during the trial;

Change from baseline in mean sitting diastolic blood pressure (msDBP) at week 12

Timeframe: Measure at week 12 of treatment.

NCT IDNCT05359068

SponsorShanghai Pharmaceuticals Holding Co., Ltd

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2023-12-26